Methods for the treatment of lung diseases with mast cell stabilizers

Abstract

Methods for the treatment of lung diseases with mast cell stabilizers are provided.

1 - 55 . (canceled) 
     
     
         56 . A pharmaceutically acceptable aerosol, comprising droplets of a solution comprising from about 2% to about 6% by weight of cromolyn sodium and an osmolarity adjusting agent consisting of sodium chloride. 
     
     
         57 . The pharmaceutically acceptable aerosol of  claim 56 , wherein said solution further comprises purified water and sodium EDTA. 
     
     
         58 . The pharmaceutically acceptable aerosol of  claim 56  or  57 , wherein said solution comprises from about 5 mg to about 80 mg of cromolyn sodium. 
     
     
         59 . The pharmaceutically acceptable aerosol of  claim 56  or  57 , wherein said solution comprises from about 36 mg to about 44 mg of cromolyn sodium. 
     
     
         60 . The pharmaceutically acceptable aerosol of  claim 56  or  57 , wherein said aerosol has a respirable fraction (≦3.3 μm) as measured by USP <1601> of at least about 30%. 
     
     
         61 . The pharmaceutically acceptable aerosol of  claim 56  or  57 , wherein said aerosol has a respirable fraction (≦3.3 μm) as measured by USP <1601> of at least about 30% and a respirable fraction (≦5 μm) as measured by USP <1601> of at least about 75%. 
     
     
         62 . The pharmaceutically acceptable aerosol of  claim 56  or  57 , wherein said osmolarity adjusting agent consists of between 0.1% to 0.7% sodium chloride, inclusive of the endpoints. 
     
     
         63 . The pharmaceutically acceptable aerosol of  claim 56  or  57 , wherein said osmolarity adjusting agent consists of between 0.1% to 0.2% sodium chloride, inclusive of the endpoints.